Clinical Trials Logo

Clinical Trial Summary

This is a multicenter, open-label, fixed dose, 26 week study of patients with MDD. Eligible patients from the lead-in studies will enter the Open-label Safety Study at the Screening/Baseline Visit (Visit 1/Day 1), at which point patient eligibility will be assessed and informed consent obtained.

Clinical Trial Description

At the Screening/Baseline Visit (Visit 1/Day 1), which is the same visit as Visit 8/Day 43 of the lead-in study, eligible patients will receive open-label lumateperone 42 mg once daily for approximately 26 weeks. Patients will continue their background ADT from the lead-in study. Patients will be seen for weekly visits through Visit 5/Week 4. Thereafter, visits will occur every two weeks. A Safety Follow-up visit will occur on Visit 17/Day 197, approximately 2 weeks after the last dose of open-label lumateperone 42 mg. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05061719
Study type Interventional
Source Intra-Cellular Therapies, Inc.
Status Enrolling by invitation
Phase Phase 3
Start date September 2021
Completion date May 2024

See also
  Status Clinical Trial Phase
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Recruiting NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Suspended NCT02940769 - Neurobiological Effects of Light on MDD Early Phase 1
Recruiting NCT04556890 - Pain and Major Depressive Disorder N/A
Recruiting NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Active, not recruiting NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Active, not recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT04799405 - Home-based tDCS in Major Depressive Disorder N/A
Recruiting NCT04422652 - Combination of Novel Therapies for CKD Comorbid Depression Phase 2
Recruiting NCT03708159 - Maintenance of Response After rTMS for Depression Using tDCS N/A
Recruiting NCT03363919 - Biomarkers in Repetitive Transcranial Magnetic Stimulation (rTMS) for Adolescent Depression N/A
Recruiting NCT04727229 - Stellate Ganglion Block for Major Depressive Disorder. Phase 4
Enrolling by invitation NCT04634669 - Open-Label Safety Study of AXS-05 in Subjects With TRD Phase 2
Recruiting NCT03307070 - Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury N/A
Completed NCT03113890 - McLean and Genomind Prospective Study N/A
Recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Recruiting NCT04130958 - Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics N/A
Not yet recruiting NCT05028738 - Patient-oriented Randomized Pragmatic Feasibility Trial With rTMS in Depression and Anxiety N/A